Accès gratuit
| Numéro |
Med Sci (Paris)
Volume 35, Numéro 12, Décembre 2019
Anticorps monoclonaux en thérapeutique
|
|
|---|---|---|
| Page(s) | 1014 - 1016 | |
| Section | Les anticorps dans les maladies autres qu’oncologiques | |
| DOI | https://doi.org/10.1051/medsci/2019224 | |
| Publié en ligne | 6 janvier 2020 | |
- Investigators EPIC. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994 ; 330: 956–961. [Google Scholar]
- Smith TW, Haber E, Yeatman L, et al. Reversal of advanced digoxin intoxication with Fab fragments of digoxin-specific antibodies. N Engl J Med 1976 ; 294: 797–800. [Google Scholar]
- Testa L, Van Gaal WJ, Bhindi R, et al. Pexelizumab in ischemic heart disease: a systematic review and meta-analysis on 15,196 patients. J Thorac Cardiovasc Surg 2008 ; 136: 884–893. [CrossRef] [PubMed] [Google Scholar]
- Baran KW, Nguyen M, McKendall GR, et al. Double-blind, randomized trial of an anti-CD18 antibody in conjunction with recombinant tissue plasminogen activator for acute myocardial infarction: limitation of myocardial infarction following thrombolysis in acute myocardial infarction (LIMIT AMI) study. Circulation 2001 ; 104: 2778–2783. [CrossRef] [PubMed] [Google Scholar]
- Rusnak JM, Kopecky SL, Clements IP, et al. An anti-CD11/CD18 monoclonal antibody in patients with acute myocardial infarction having percutaneous transluminal coronary angioplasty (the FESTIVAL study). Am J Cardiol 2001 ; 88: 482–487. [CrossRef] [PubMed] [Google Scholar]
- Stähli BE, Gebhard C, Duchatelle V, et al. Effects of the P-selectin antagonist Inclacumab on myocardial damage after percutaneous coronary intervention according to timing of infusion: Insights from the SELECT-ACS trial. J Am Heart Assoc 2016; 5. [Google Scholar]
- Carroll MB, Haller C, Smith C. Short-term application of tocilizumab during myocardial infarction (STAT-MI). Rheumatol Int 2018 ; 38: 59–66. [Google Scholar]
- Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory therapy with Canakinumab for atherosclerotic disease. N Engl J Med 2017 ; 377: 1119–1131. [Google Scholar]
- Ridker PM, MacFadyen JG, Thuren T, et al. Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial. Lancet 2017 ; 390: 1833–1842. [CrossRef] [PubMed] [Google Scholar]
- Abifadel M, Varret M, Rabès JP, et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet 2003 ; 34: 1546. [Google Scholar]
- Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 2017 ; 376: 17: 1322. [Google Scholar]
- Schwartz GG, Steg PG, Szarek M, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med 2018 ; 379: 2097–2107. [Google Scholar]
- Ridker PM, Revkin J, Amarenco P, et al. Cardiovascular efficacy and safety of Bococizumab in high-risk patients. N Engl J Med 2017 ; 376: 1527–1539. [Google Scholar]
- Stoekenbroek RM, Kallend D, Wijngaard PL, et al. Inclisiran for the treatment of cardiovascular disease: the ORION clinical development program. Future Cardiol 2018 ; 14: 433–442. [CrossRef] [PubMed] [Google Scholar]
- Daifotis AG, Koenig S, Chatenoud L, et al. Anti-CD3 clinical trials in type 1 diabetes mellitus. Clin Immunol 2013 ; 149: 268–278. [CrossRef] [PubMed] [Google Scholar]
Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.
Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.
Le chargement des statistiques peut être long.